NCT06341894View on ClinicalTrials.gov

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

1,163

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions
Early Breast Cancer
Interventions
DRUG

Dalpiciclib

CDK4/6 inhibitor dalpiciclib, 100mg orally qd

DRUG

Endocrine therapy

Fulvestrant/AI

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER